DBV Technologies | DBVT - Sales Revenues


DBV Technologies reported $2.77M in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
Acadia Pharmaceuticals USD 278.6M 14M Sep/2025
Alnylam Pharmaceuticals USD 1.25B 476.31M Sep/2025
Amarin USD 49.67M 23.07M Sep/2025
BioMarin Pharmaceutical USD 776M 49M Sep/2025
DBV Technologies USD 2.77M 1.31M Sep/2025
Halozyme Therapeutics USD 354M 148M Sep/2025
Incyte USD 1.37B 310M Sep/2025
Insmed USD 142M 34.6M Sep/2025
Ionis Pharmaceuticals USD 157M 295M Sep/2025
Neurocrine Biosciences USD 794.9M 107.4M Sep/2025
PTC Therapeutics USD 211M 32.1M Sep/2025
Sarepta Therapeutics USD 399.4M 211.69M Sep/2025
Ultragenyx Pharmaceutical USD 160M 6.5M Sep/2025
United Therapeutics USD 799.5M 900K Sep/2025